Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORTEN: Omalizumab Withdrawal in Severe Asthma
NCT04763447Phase 4Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2021
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in allergic asthma, sponsored by Assistance publique - Hôpitaux de Paris. Started May 2021; status: recruiting.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT04763447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04763447.